Exact Sciences disclosed new evidence supporting its Oncodetect MRD test in early triple-negative breast cancer, presented by collaborators at AACR. The research reported an association between ctDNA positivity and a lack of pathologic complete response (pCR) following neoadjuvant treatment. The finding reinforces the role of circulating tumor DNA as a potential biomarker for treatment response in aggressive breast cancer subtypes, where pCR remains a key outcome measure. Exact Sciences did not provide additional regulatory or clinical action triggers in the available report. For MRD and liquid biopsy developers, the update adds to the expanding dataset used to justify earlier and more actionable monitoring strategies across oncology trials and care pathways.